文献速递银屑病与炎症性皮肤病

IL-23抑制剂tildrakizumab与guselkumab治疗银屑病的III期试验数据综述

Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-07-17

本综述汇总了靶向IL-23的单克隆抗体tildrakizumab与guselkumab的III期临床试验数据,用以评估两种药物的安全性和疗效。结果显示,在第12周时,两种药物各自最有效剂量组中达到PASI 75的患者比例均超过60%;guselkumab的III期试验主要终点为第16周PASI 90,达到该终点的患者比例超过70%。两种药物的安全性特征相当,最常见的不良事件为鼻咽炎和上呼吸道感染。

要点

  • 两种抗IL-23药物最有效剂量组第12周PASI 75比例均超过60%。
  • guselkumab第16周PASI 90(主要终点)比例超过70%。
  • 常见不良事件为鼻咽炎和上呼吸道感染,短期安全性良好。

核心结论

  • 抗IL-23药物可快速改善银屑病,疗效与现有IL-17抑制剂相似或更优,短期安全性良好。
  • III期试验结果支持IL-23是银屑病治疗的潜在靶点。

研究设计与样本

  • 综述tildrakizumab与guselkumab的III期临床试验结果;risankizumab的III期结果尚未报告。

主要发现

  • 第12周时,两种药物各自最有效剂量组达到PASI 75的患者比例均超过60%。
  • guselkumab的III期试验以第16周PASI 90为主要终点,达到该终点的患者比例超过70%。
  • 两种药物安全性特征相当,最常见不良事件为鼻咽炎和上呼吸道感染。

关键数值与推荐

  • 第12周PASI 75:两种药物最有效剂量组均超过60%。
  • 第16周PASI 90(guselkumab主要终点):超过70%。

临床怎么用

  • 可将抗IL-23药物作为银屑病系统治疗的候选方案,关注短期上呼吸道感染与鼻咽炎。

局限性

  • risankizumab的III期试验结果尚未报告,未纳入本综述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of monoclonal antibodies targeting IL-12 and IL-23 has enhanced the therapeutic options available for psoriasis patients. Recent research suggests that IL-23 alone plays a role in the pathogenesis of psoriasis. The objective was to review the phase III clinical trial data for the anti-IL-23 agents to evaluate the safety and efficacy profile of each agent. We reviewed the results of the phase III clinical trials for the anti-IL-23 agents tildrakizumab and guselkumab. The results of phase III trials on risankizumab have not yet been reported. By week 12, the proportion of patients reaching Psoriasis Area and Severity Index (PASI 75) was >60% among the most efficacious dose of each agent. The percentage of patients achieving PASI 90 at week 16 was the primary endpoint for the phase III trials for guselkumab, which was above 70%. The safety profiles of the agents were comparable, with the most commonly reported adverse events of nasopharyngitis and upper respiratory tract infections. The anti-IL-23 agents demonstrated a rapid clinical improvement that is similar or superior to the improvement seen with currently marketed IL-17 inhibitors with a favourable short-term safety profile. The results of the phase III trials support the notion that IL-23 is a potential target in psoriasis treatment.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Amin M, Darji K, No DJ, et al. Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis. J Eur Acad Dermatol Venereol. 2017. PMID: 28667777. doi:10.1111/jdv.14451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。